DiaMedica Therapeutics Inc logo

DMA - DiaMedica Therapeutics Inc Share Price

C$4.63 -0.1  -2.1%

Last Trade - 18/01/19

Sector
Healthcare
Size
Small Cap
Market Cap £79.0m
Enterprise Value £69.3m
Revenue £n/a
Position in Universe th / 2675
Bullish
Bearish
Unlock DMA Revenue
Momentum
Relative Strength (%)
1m +7.35%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.50 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, DiaMedica Therapeutics Inc revenues was not reported. Net loss decreased 25% to $2.4M. Lower net loss reflects Research and development decrease of 47% to $1.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.27 to -$0.19.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

DMA Revenue Unlock DMA Revenue

Net Income

DMA Net Income Unlock DMA Revenue

Normalised EPS

DMA Normalised EPS Unlock DMA Revenue

PE Ratio Range

DMA PE Ratio Range Unlock DMA Revenue

Dividend Yield Range

DMA Dividend Yield Range Unlock DMA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DMA EPS Forecasts Unlock DMA Revenue
Profile Summary

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of recombinant (synthetic) proteins. The Company uses its technologies for the development and commercialization of recombinant proteins to treat kidney and neurological diseases. The Company’s focus is on chronic kidney disease (CKD) and acute ischemic stroke (AIS). The Company’s lead product DM199, is a drug candidate, a commercial potential as a therapy for CKD and AIS. DM199 is a recombinant form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) produced primarily in the kidneys, pancreas and salivary glands that plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels, which decreases vascular resistance) in the body, as well as an important role in inflammation and oxidative stress.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated January 21, 2000
Public Since February 29, 2012
No. of Shareholders: n/a
No. of Employees: 8
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange TSX Venture Exchange
Shares in Issue 14,139,074
Free Float (0.0%)
Eligible for
ISAs
SIPPs
DMA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DMA
Upcoming Events for DMA
Frequently Asked Questions for DiaMedica Therapeutics Inc
What is the DiaMedica Therapeutics Inc share price?

As of 18/01/19, shares in DiaMedica Therapeutics Inc are trading at C$4.63, giving the company a market capitalisation of £79.0m. This share price information is delayed by 15 minutes.

How has the DiaMedica Therapeutics Inc share price performed this year?

Shares in DiaMedica Therapeutics Inc are currently trading at C$4.63 and the price has moved by -22.83% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the DiaMedica Therapeutics Inc price has moved by -23.94% over the past year.

What are the analyst and broker recommendations for DiaMedica Therapeutics Inc?

Of the analysts with advisory recommendations for DiaMedica Therapeutics Inc, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for DiaMedica Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will DiaMedica Therapeutics Inc next release its financial results?

DiaMedica Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the DiaMedica Therapeutics Inc dividend yield?

DiaMedica Therapeutics Inc does not currently pay a dividend.

Does DiaMedica Therapeutics Inc pay a dividend?

DiaMedica Therapeutics Inc does not currently pay a dividend.

When does DiaMedica Therapeutics Inc next pay dividends?

DiaMedica Therapeutics Inc does not currently pay a dividend.

How do I buy DiaMedica Therapeutics Inc shares?

To buy shares in DiaMedica Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of DiaMedica Therapeutics Inc?

Shares in DiaMedica Therapeutics Inc are currently trading at C$4.63, giving the company a market capitalisation of £79.0m.

Where are DiaMedica Therapeutics Inc shares listed? Where are DiaMedica Therapeutics Inc shares listed?

Here are the trading details for DiaMedica Therapeutics Inc:

Country of listing: Canada
Exchange: CVE
Ticker Symbol: DMA
What kind of share is DiaMedica Therapeutics Inc?

We were not able to load our ranking data for DiaMedica Therapeutics Inc

Is there a DiaMedica Therapeutics Inc share price forecast 2020?

We were not able to load any forecast data for DiaMedica Therapeutics Inc.

How can I tell whether the DiaMedica Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DiaMedica Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -61.89%. At the current price of C$4.63, shares in DiaMedica Therapeutics Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the DiaMedica Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for DiaMedica Therapeutics Inc.

Who are the key directors of DiaMedica Therapeutics Inc?

DiaMedica Therapeutics Inc's management team is headed by:

Rick Pauls - PRE
Richard Pilnik - CHM
Michael Giuffre - IND
James Parsons - DRC
Todd Verdoorn - CSO
Jerry Xiao - DRC
Paul Papi - VBD
Scott Kellen - CFO
Harry Alcorn - DRC
Sydney Gilman - VPR
Who are the major shareholders of DiaMedica Therapeutics Inc?

Here are the top five shareholders of DiaMedica Therapeutics Inc based on the size of their shareholding:

Xiao (Zhenyu) Individual Investor
Percentage owned: 7.12% (1.01m shares)
Hermeda Industrial Co., Ltd. Corporation
Percentage owned: 7.07% (1,000k shares)
Hirschman (Orin) Individual Investor
Percentage owned: 6.32% (759k shares)
Stonepine Capital Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 5.84% (825k shares)
Nantahala Capital Management, LLC Hedge Fund
Percentage owned: 5.3% (750k shares)
Similar to DMA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.